Please login to the form below
11
Revenue 2017AstraZeneca
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AstraZeneca's 2013 sales performance.
Resetting Customer Relationships
by AstraZeneca. with support from Ashfield Excellence Academy. ... A Sporting Games Initiative to Boost Learner Engagement - by AstraZeneca.
LiverSync®
by AstraZeneca. with support from Real Chemistry. ... Break Over-Reliance - by AstraZeneca. with support from Real Chemistry.
NRAS Patient Chatbot
by AstraZeneca. with support from GCI Health and Engine MHP. ... New Normal, Same Cancer - by AstraZeneca. with support from GCI Health and Engine MHP.
Supporting Head and Neck Cancer Patients Return to Work Following Treatment
by AstraZeneca. with support from MHP Communications and GCI. ... New Normal, Same Cancer - by AstraZeneca. with support from MHP Communications and GCI.
Myeloproliferative Neoplasms Virtual Speaker Training Program 2021
by AstraZeneca. with support from Real Chemistry. ... Break Over-Reliance - by AstraZeneca. with support from Real Chemistry.
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
Head of Copy
-
£ competitive
- Pfizer CEO announces plans to launch Omicron-specific COVID-19 vaccine
- AstraZeneca's Enhertu receives FDA grant for priority review
- Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics
- Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US
- AstraZeneca’s Vaxzevria trial provides further support for protection against COVID-19 variants
- BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Pfizer CEO announces plans to launch Omicron-specific COVID-19 vaccine
- EU cross-border healthcare
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- Pfizer's 2021 revenue predictions soar to $82bn
- Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Hybrid working: Insights and tips for success
- Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
- The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
- Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
- How to innovate and influence people in times of misinformation
- The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
